For US Healthcare
Professionals Only

Learn About BELVIQ

A new treatment for chronic weight management

Chronic Weight Management Efficacy

See how BELVIQ performed

Changes in Metabolic Parameters

See how BELVIQ affected glycemic control, blood pressure, and lipid profiles

Safety Profile

View adverse reactions and CV evaluation from the pivotal trials

Physician Resources and Support

Get exclusive access to pivotal trial papers, webcasts, and more

Indication

BELVIQ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes).

Limitations of Use: The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss, including prescription drugs (eg, phentermine), over-the-counter drugs, and herbal preparations, have not been established. The effect of BELVIQ on cardiovascular morbidity and mortality has not been established.

Important Safety Information

Contraindication

Warnings and Precautions

Most Common Adverse Reactions

Nursing Mothers

BELVIQ® is a federally controlled substance that may lead to abuse or dependence.

For more information about BELVIQ®, see full Prescribing Information.

Alert:

The email you provided is already registered in our system. Please try again. If you prefer, you may contact Eisai Medical Information using the Med Info Chat or by calling 1-888-274-2378 for further assistance (Monday through Friday, 8:30 AM to 5:00 PM, Eastern Time).

Alert:

The information you have provided is not recognized in our system. Please try again. If you prefer, you may contact Eisai Medical Information using the Med Info Chat or by calling 1-888-274-2378 for further assistance (Monday through Friday, 8:30 AM to 5:00 PM, Eastern Time).